Modified protocol for desensitization to glatiramer acetate.
Sheth
Shashank S
SS
Posner
Mark A
MA
D000328:Adult; D017024:Chemotherapy, Adjuvant; D002985:Clinical Protocols; D003888:Desensitization, Immunologic; D004155:Diphenhydramine / Q000627:therapeutic use; D054796:Drug Dosage Calculations; D004342:Drug Hypersensitivity / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology; D015508:Nasal Obstruction; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011537:Pruritus; D014581:Urticaria
D010455:Peptides; D000068717:Glatiramer Acetate; D004155:Diphenhydramine; D011241:Prednisone